<DOC>
	<DOC>NCT00224055</DOC>
	<brief_summary>This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic agents (hormones that stimulate the bone marrow to make more red blood cells).</brief_summary>
	<brief_title>Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Moderate to severe anemia Iron deficiency Moderate to severe chronic kidney disease Receiving dialysis Known sensitivity to Ferrlecit® or any of its components Receiving therapy with erythropoietic agent Clinically unstable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Iron deficiency</keyword>
	<keyword>Anemia</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Sodium Ferric Gluconate</keyword>
	<keyword>Anemia, Iron-Deficiency/drug therapy/etiology</keyword>
	<keyword>Kidney Failure, Chronic/blood/complications/therapy</keyword>
</DOC>